CNS5:Pleomorphic xanthoastrocytoma: Difference between revisions
| [unchecked revision] | [unchecked revision] |
| Line 84: | Line 84: | ||
|'''Rare (<5%) PMID: 37870438''' | |'''Rare (<5%) PMID: 37870438''' | ||
|D | |D | ||
|Context-dependent ( e.g. For patients with CNS tumors who harbor NTRK fusions, TRK inhibitors such as larotrectinib or repotrectinib are considered a preferred therapy, regardless of histology, if other options are limited) NCCN CNS Cancer guidelines | |Context-dependent ( e.g. For patients with CNS tumors who harbor NTRK fusions, TRK inhibitors such as larotrectinib or repotrectinib are considered a preferred therapy, regardless of histology, if other options are limited) NCCN CNS Cancer guidelines | ||
|Reported in individual cases; more common in glioneuronal/low-grade gliomas | |Reported in individual cases; more common in glioneuronal/low-grade gliomas | ||
|- | |- | ||
| Line 110: | Line 110: | ||
|CDKN2A, CDKN2B | |CDKN2A, CDKN2B | ||
|D, P | |D, P | ||
|Yes (WHO CNS5, NCCN) | |Yes (WHO CNS5, NCCN) | ||
|'''Defining PXA feature; occurs in >85% of cases (PMID: 28181325)''' | |'''Defining PXA feature; occurs in >85% of cases (PMID: 28181325)''' | ||
|- | |- | ||
| Line 118: | Line 118: | ||
|EGFR not typically amplified) | |EGFR not typically amplified) | ||
|D | |D | ||
|No (however, frequently mentioned in literature as a recurrent copy number change in PXA (PMID: | |No (however, frequently mentioned in literature as a recurrent copy number change in PXA (PMID: | ||
| | |Frequent but non-specific; supports PXA diagnosis | ||
|- | |- | ||
|<span class="blue-text">EXAMPLE:</span> | |<span class="blue-text">EXAMPLE:</span> | ||